Items Tagged ‘PALOMA3 trial’

March 17th, 2016

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer


The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor receptor-2 (HER2)-negative, metastatic breast cancer that has progressed following prior endocrine (hormone) therapy. The majority of breast cancers are HR-positive. These cancers are stimulated to grow by the […]

View full entry

Tags: approval, Breast Cancer, Faslodex, fda, fulvestrant, HER2-negative, hormone-positive, Ibrance, metastatic, Metastatic Breast Cancer, News, palbociclib